Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcadia Biosciences (RKDA) EBIT Margin (2016 - 2025)

Arcadia Biosciences filings provide 12 years of EBIT Margin readings, the most recent being 70.37% for Q4 2025.

  • On a quarterly basis, EBIT Margin rose 7917.0% to 70.37% in Q4 2025 year-over-year; TTM through Dec 2025 was 10.07%, a 1917.0% increase, with the full-year FY2025 number at 10.11%, up 1915.0% from a year prior.
  • EBIT Margin hit 70.37% in Q4 2025 for Arcadia Biosciences, up from 88.48% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 151.61% in Q2 2024 to a low of 643.24% in Q1 2021.
  • Median EBIT Margin over the past 5 years was 103.02% (2022), compared with a mean of 93.87%.
  • The widest YoY moves for EBIT Margin: up 244633bps in 2021, down -143288bps in 2021.
  • Arcadia Biosciences' EBIT Margin stood at 130.0% in 2021, then crashed by -38bps to 80.14% in 2022, then crashed by -292bps to 153.54% in 2023, then soared by 94bps to 8.8% in 2024, then soared by 900bps to 70.37% in 2025.
  • The last three reported values for EBIT Margin were 70.37% (Q4 2025), 88.48% (Q3 2025), and 34.43% (Q2 2025) per Business Quant data.